A real-world study presented at ECO 2025 shows members in Embla’s digital program achieved the same weight loss as seen in semaglutide trials — with significantly lower doses of the drug.

Discover how employers are reducing GLP-1 costs while improving outcomes. Learn the key strategies behind sustainable coverage that actually works.

GLP-1s like Wegovy are powerful — but expensive. Learn how employers can reduce costs and improve outcomes by delivering structured support and behavior change.

Heart disease is still the leading cause of death in the U.S. — and a silent driver of absenteeism, fatigue, and rising healthcare costs. Here's how employers can proactively support cardiovascular health and boost workforce resilience.

GLP-1 drugs like Wegovy, Mounjaro and Ozempic are highly effective — but costly. Learn how self-funded employers can reduce spend and improve outcomes with a structured, coaching-based approach.

Learn how self-funded employers can control cost and improve outcomes by offering GLP-1s with structure, coaching, and dose management.

Learn how to design, launch, and scale a GLP-1 weight loss benefit for employees that actually delivers outcomes — without blowing your budget.

Learn how employers can add GLP-1-based weight loss support to their health plans — without losing control of cost, outcomes, or operations.

Learn how modern digital wellness programs help employers lower costs, improve outcomes, and manage GLP-1 spend — all while delivering truly personalized care at scale

Most employee wellness programs fail to deliver ROI. Learn how to build one that works — with clinically backed, behavior-first strategies that reduce claims and improve long-term health.

See why DIY apps don’t deliver sustainable weight loss — and how coaching-first programs like Embla help members lose more weight, use less medication, and reduce employer costs.

Embla combines behavior-first coaching with strategic medication use to achieve 16.7% average weight loss using 66% less GLP-1. Here’s how our model delivers lasting results, lower spend, and better outcomes for employers.

Most employee wellness programs underdeliver because they rely on generic tools and lack accountability. Here's why coaching-based models are different — and how employers can reduce GLP-1 spend, improve engagement, and deliver better ROI.

Confusion around GLP-1s like Wegovy and Zepbound is everywhere. Here’s what employers, benefit advisors, and employees need to know about how weight loss medications really work — and what doesn’t.

GLP-1 costs are exploding — but not for the reasons you think. Learn what’s really driving your pharmacy spend and how to control it with smarter dose management, coaching, and tapering support.

Not all weight loss vendors are created equal. Learn the five key questions every employer should ask to ensure clinical safety, cost control, and lasting results.

GLP-1s alone lead to short-term results — and long-term costs. Discover why coaching is critical to helping employees lose weight sustainably and reducing employer pharmacy spend.

GLP-1s are in demand — but open-access models lead to high costs and fragile results. Learn how self-funded employers can design a more sustainable GLP-1 benefit.

GLP-1s deliver fast weight loss — but without behavior change, results rarely last. Discover how combining medication with coaching creates better outcomes and controls long-term costs for employers.